Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4759352
Max Phase: Preclinical
Molecular Formula: C64H95N25O17S4
Molecular Weight: 1614.89
Molecule Type: Unknown
Associated Items:
ID: ALA4759352
Max Phase: Preclinical
Molecular Formula: C64H95N25O17S4
Molecular Weight: 1614.89
Molecule Type: Unknown
Associated Items:
Canonical SMILES: C[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@@H]2CSSC[C@@H](C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNC(=O)[C@@H](N)CC(N)=O)C(=O)N2)NC1=O
Standard InChI: InChI=1S/C64H95N25O17S4/c1-32-52(95)86-44-27-108-110-29-46(87-56(99)38(12-7-15-73-64(69)70)80-49(92)23-74-53(96)36(66)20-48(67)91)61(104)88-45(60(103)83-41(19-35-22-72-31-77-35)63(106)89-16-8-13-47(89)62(105)78-32)28-109-107-26-43(51(68)94)85-59(102)42(25-90)84-57(100)39(17-33-9-3-2-4-10-33)81-58(101)40(18-34-21-71-30-76-34)82-55(98)37(11-5-6-14-65)79-50(93)24-75-54(44)97/h2-4,9-10,21-22,30-32,36-47,90H,5-8,11-20,23-29,65-66H2,1H3,(H2,67,91)(H2,68,94)(H,71,76)(H,72,77)(H,74,96)(H,75,97)(H,78,105)(H,79,93)(H,80,92)(H,81,101)(H,82,98)(H,83,103)(H,84,100)(H,85,102)(H,86,95)(H,87,99)(H,88,104)(H4,69,70,73)/t32-,36-,37-,38-,39-,40-,41-,42-,43-,44-,45-,46-,47-/m0/s1
Standard InChI Key: ZLONTHJBFIAWQI-DQJPWBRISA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1614.89 | Molecular Weight (Monoisotopic): 1613.6221 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Giribaldi J,Haufe Y,Evans ERJ,Amar M,Durner A,Schmidt C,Faucherre A,Moha Ou Maati H,Enjalbal C,Molgó J,Servent D,Wilson DT,Daly NL,Nicke A,Dutertre S. (2020) Backbone Cyclization Turns a Venom Peptide into a Stable and Equipotent Ligand at Both Muscle and Neuronal Nicotinic Receptors., 63 (21.0): [PMID:33063995] [10.1021/acs.jmedchem.0c00957] |
Source(1):